[F]DPA-714: Effect of Co-medications, Age, Sex, BMI and TSPO Polymorphism on the Human Plasma Input Function

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2023 Jun 8

PMID 37291448

Authors

M A Peyronneau

B Kuhnast

D-L Nguyen

B Jego

G Sayet

F Caille

S Lavisse

P Gervais

B Stankoff

M Sarazin

P Remy

V Bouilleret

C Leroy

M Bottlaender

Affiliations

Soon will be listed here.

Abstract

Purpose: We aimed to assess the effect of concomitant medication, age, sex, body mass index and 18-kDa translocator protein (TSPO) binding affinity status on the metabolism and plasma pharmacokinetics of [F]DPA-714 and their influence on the plasma input function in a large cohort of 201 subjects who underwent brain and whole-body PET imaging to investigate the role of neuroinflammation in neurological diseases.

Methods: The non-metabolized fraction of [F]DPA-714 was estimated in venous plasma of 138 patients and 63 healthy controls (HCs; including additional arterial sampling in 16 subjects) during the 90 min brain PET acquisition using a direct solid-phase extraction method. The mean fraction between 70 and 90 min post-injection ([F]DPA-714) and corresponding normalized plasma concentration (SUV) were correlated with all factors using a multiple linear regression model. Differences between groups (arterial vs venous measurements; HCs vs patients; high- (HAB), mixed- (MAB) and low-affinity binders (LAB); subjects with vs without co-medications, females vs males were also assessed using the non-parametric Mann-Whitney or Kruskal-Wallis ANOVA tests. Finally, the impact of co-medications on the brain uptake of [F]DPA-714 at equilibrium was investigated.

Results: As no significant differences were observed between arterial and venous [F]DPA-714 and SUV, venous plasma was used for correlations. [F]DPA-714 was not significantly different between patients and HC (59.7 ± 12.3% vs 60.2 ± 12.9%) despite high interindividual variability. However, 47 subjects exhibiting a huge increase or decrease of [F]DPA-714 (up to 88% or down to 23%) and SUV values (2-threefold) were found to receive co-medications identified as inhibitors or inducers of CYP3A4, known to catalyse [F]DPA-714 metabolism. Comparison between cortex-to-plasma ratios using individual input function (VT) or population-based input function derived from untreated HCs (VT) indicated that non-considering the individual metabolism rate led to a bias of about 30% in VT values. Multiple linear regression model analysis of subjects free of these co-medications suggested significant correlations between [F]DPA-714 and age, BMI and sex while TSPO polymorphism did not influence the metabolism of the radiotracer. [F]DPA-714 metabolism fell with age and BMI and was significantly faster in females than in males. Whole-body PET/CT exhibited a high uptake of the tracer in TSPO-rich organs (heart wall, spleen, kidneys…) and those involved in metabolism and excretion pathways (liver, gallbladder) in HAB and MAB with a strong decrease in LAB (-89% and -85%) resulting in tracer accumulation in plasma (4.5 and 3.3-fold increase).

Conclusion: Any co-medication that inhibits or induces CYP3A4 as well as TSPO genetic status, age, BMI and sex mostly contribute to interindividual variations of the radiotracer metabolism and/or concentration that may affect the input function of [F]DPA-714 and consequently its human brain and peripheral uptake.

Trial Registration: INFLAPARK, NCT02319382, registered December 18, 2014, retrospectively registered; IMABIO 3, NCT01775696, registered January 25, 2013, retrospectively registered; INFLASEP, NCT02305264, registered December 2, 2014, retrospectively registered; EPI-TEP, EudraCT 2017-003381-27, registered September 24, 2018.

Citing Articles

A novel blood-free analytical framework for the quantification of neuroinflammatory load from TSPO PET Imaging.

Maccioni L, Brusaferri L, Barzon L, Schubert J, Nettis M, Cousins O Res Sq. 2025; .

PMID: 39975931 PMC: 11838776. DOI: 10.21203/rs.3.rs-5924801/v1.

Microglial Positron Emission Tomography Imaging In Vivo : Positron Emission Tomography Radioligands: Utility in Research and Clinical Practice.

Ottoy J, De Picker L, Kang M Adv Neurobiol. 2024; 37:579-589.

PMID: 39207714 DOI: 10.1007/978-3-031-55529-9_32.

A blood-free modeling approach for the quantification of the blood-to-brain tracer exchange in TSPO PET imaging.

Maccioni L, Michelle C, Brusaferri L, Silvestri E, Bertoldo A, Schubert J Front Neurosci. 2024; 18:1395769.

PMID: 39104610 PMC: 11299498. DOI: 10.3389/fnins.2024.1395769.

Tau induces inflammasome activation and microgliosis through acetylating NLRP3.

Zhang L, Gai Y, Liu Y, Meng D, Zeng Y, Luo Y Clin Transl Med. 2024; 14(3):e1623.

PMID: 38488468 PMC: 10941548. DOI: 10.1002/ctm2.1623.

References

Cosenza-Nashat M, Zhao M, Suh H, Morgan J, Natividad R, Morgello S . Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2008; 35(3):306-28. PMC: 2693902. DOI: 10.1111/j.1365-2990.2008.01006.x. View

Li Z, Xu J, Lang Y, Wu X, Hu S, Samrat S . and characterization of erythrosin B and derivatives against Zika virus. Acta Pharm Sin B. 2022; 12(4):1662-1670. PMC: 9279632. DOI: 10.1016/j.apsb.2021.10.017. View

Hamelin L, Lagarde J, Dorothee G, Potier M, Corlier F, Kuhnast B . Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease. Brain. 2018; 141(6):1855-1870. DOI: 10.1093/brain/awy079. View

Bodini B, Poirion E, Tonietto M, Benoit C, Palladino R, Maillart E . Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis. J Nucl Med. 2020; 61(7):1043-1049. PMC: 7383077. DOI: 10.2967/jnumed.119.231340. View

Lavisse S, Goutal S, Wimberley C, Tonietto M, Bottlaender M, Gervais P . Increased microglial activation in patients with Parkinson disease using [F]-DPA714 TSPO PET imaging. Parkinsonism Relat Disord. 2020; 82:29-36. DOI: 10.1016/j.parkreldis.2020.11.011. View

Kosuda S, Kawahara S, Ishibashi A, Tamura K, Tsukatani Y, Fujii H . Usefulness of pinhole collimator in differential diagnosis of metastatic disease and degenerative joint disease in the vertebrae; evaluation by receiver operating characteristics (ROC) analysis. Ann Nucl Med. 1989; 3(3):119-24. DOI: 10.1007/BF03178297. View

Chauveau F, Van Camp N, Dolle F, Kuhnast B, Hinnen F, Damont A . Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammation. J Nucl Med. 2009; 50(3):468-76. DOI: 10.2967/jnumed.108.058669. View

James M, Fulton R, Vercoullie J, Henderson D, Garreau L, Chalon S . DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med. 2008; 49(5):814-22. DOI: 10.2967/jnumed.107.046151. View

Lavisse S, Inoue K, Jan C, Peyronneau M, Petit F, Goutal S . [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain. Eur J Nucl Med Mol Imaging. 2014; 42(3):478-94. DOI: 10.1007/s00259-014-2962-9. View

10.

Arlicot N, Vercouillie J, Ribeiro M, Tauber C, Venel Y, Baulieu J . Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl Med Biol. 2011; 39(4):570-8. DOI: 10.1016/j.nucmedbio.2011.10.012. View

11.

Yrondi A, Aouizerate B, El-Hage W, Moliere F, Thalamas C, Delcourt N . Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study). Front Psychiatry. 2018; 9:326. PMC: 6066663. DOI: 10.3389/fpsyt.2018.00326. View

12.

Backhaus P, Roll W, Beuker C, Zinnhardt B, Seifert R, Wenning C . Initial experience with [F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system. Eur J Nucl Med Mol Imaging. 2020; 47(9):2131-2141. PMC: 7338821. DOI: 10.1007/s00259-019-04662-4. View

13.

Owen D, Yeo A, Gunn R, Song K, Wadsworth G, Lewis A . An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2011; 32(1):1-5. PMC: 3323305. DOI: 10.1038/jcbfm.2011.147. View

14.

Peyronneau M, Saba W, Goutal S, Damont A, Dolle F, Kassiou M . Metabolism and quantification of [(18)F]DPA-714, a new TSPO positron emission tomography radioligand. Drug Metab Dispos. 2012; 41(1):122-31. DOI: 10.1124/dmd.112.046342. View

15.

Li Z, Jiang Y, Guengerich F, Ma L, Li S, Zhang W . Engineering cytochrome P450 enzyme systems for biomedical and biotechnological applications. J Biol Chem. 2019; 295(3):833-849. PMC: 6970918. DOI: 10.1074/jbc.REV119.008758. View

16.

Vicente-Rodriguez M, Singh N, Turkheimer F, Peris-Yague A, Randall K, Veronese M . Resolving the cellular specificity of TSPO imaging in a rat model of peripherally-induced neuroinflammation. Brain Behav Immun. 2021; 96:154-167. PMC: 8323128. DOI: 10.1016/j.bbi.2021.05.025. View

17.

Fang Y, McConathy J, Yacoubian T, Zhang Y, Kennedy R, Standaert D . Image Quantification for TSPO PET with a Novel Image-Derived Input Function Method. Diagnostics (Basel). 2022; 12(5). PMC: 9140104. DOI: 10.3390/diagnostics12051161. View

18.

Wimberley C, Lavisse S, Hillmer A, Hinz R, Turkheimer F, Zanotti-Fregonara P . Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain. Eur J Nucl Med Mol Imaging. 2021; 49(1):246-256. PMC: 8712306. DOI: 10.1007/s00259-021-05248-9. View

19.

Kuhnast B, Damont A, Hinnen F, Catarina T, Demphel S, Le Helleix S . [18F]DPA-714, [18F]PBR111 and [18F]FEDAA1106-selective radioligands for imaging TSPO 18 kDa with PET: automated radiosynthesis on a TRACERLAb FX-FN synthesizer and quality controls. Appl Radiat Isot. 2011; 70(3):489-97. DOI: 10.1016/j.apradiso.2011.10.015. View

20.

Ma B, Prueksaritanont T, Lin J . Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000; 28(2):125-30. View